Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265603 · ClinicalTrials.gov registry record · Phase 1
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00265603 is a Phase 1 study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 16 participants.
The verdict
NCT00265603, a Phase 1 study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization uses a device called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day.
Interventions
- PROCEDURE Extracorporeal Photochemotherapy With Transimmunization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265603
The ClinicalTrials.gov registry entry for NCT00265603 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extracorporeal Photochemotherapy With Transimmunization is the first listed.
NCT00265603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265603 about?
NCT00265603 is a clinical study titled "Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer". The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization u...
What is the current status of trial NCT00265603?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2004-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00265603?
The interventions under investigation include: Extracorporeal Photochemotherapy With Transimmunization (PROCEDURE).
Who is sponsoring clinical trial NCT00265603?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.